At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating Meloxicam 15 mg po QD and Cognitive Behavioral Therapy for Knee Osteoarthritis. Completed, enrolled 490 participants across 4 sites.
Detailed Summary
Knee osteoarthritis (OA) is now recognized as a major health problem. It is the number one cause of lower extremity disability and has significant deleterious effects on quality of life. While there are numerous therapies available for knee OA, most have limited efficacy. Of particular concern, is the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) for this disorder. Veterans, as a group, are at high risk for both gastrointestinal and cardiovascular NSAID-induced complications. In this study the investigators propose to examine whether replacing NSAIDs with cognitive behavioral therapy delivered by telephone is an effective strategy for Veterans with knee OA. Telephone-administered therapy is particularly appealing since Veterans with knee OA are more likely to have limited mobility. If successful, this program may result in significant cost-savings for both Veterans (decreased co-pays and transportation costs) and the VA (decreased hospitalizations due to NSAID induced toxicity).
Study Details
Timeline
Interventions
Eligible subjects will be take Meloxicam 15 mg po QD
Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks